Latest Content

Dry eye questionnaires capture only 22.4% of Demodex blepharitis symptoms, and a 22-study review links Demodex infestation to worse meibomian gland function.

Neda Gioia, OD, CNS, FMCP, FOWNS, CFMP, details a lack of research exploring the intersection of hormones and ocular health in women and what health care as a whole should investigate next.

Shane Kannarr, OD, overviews results from a phase 4, multicenter, prospective, open-label trial that evaluated the impact of concomitant use of PFHO during contact lens wear.

Real-world PFHO data show OSDI scores falling within 2 weeks, while a 12-month trial finds stable corneal endothelial cell density with cyclosporine 0.1%.

Christopher W. Lievens, OD, MS, PhD, FAAO, FNAP, FBCLA, discusses his poster presentation titled "Latanoprostene bunod 0.024% Initiation in Medicare Fee-for-Service Patients with Open Angle Glaucoma and Ocular Hypertension."

To kick off Perimenopause and Menopause Awareness Month, Meredith Bishop, OD, MS, FAAO, gives an overview of her poster "Perceptions of Linking Presbyopia with Perimenopause: A Survey of US Female Eye Care Professionals."

Michael Cymbor, OD, FAAO, gives an overview of a rapid fire lecture he gave in collaboration with Andrew Rixon OD, FAAO; Austin Lifferth, OD, FAAO; and Derek MacDonald, OD, FAAO, at AAOpt 2026.

Clark Chang, OD, MSA, MSc, FAAO, discussed his presentation at AAOpt 2026 titled "A New Era in Corneal Surgery for Keratoconus."

Three experts explain why CVI can hide behind a normal eye exam and why early referral matters.

David Webley, BSc (Hons), MCOptom, FBCLA, weighs in on SightGlass Vision's latest data presented at AAOpt's annual meeting in Anaheim, California.

To close out Sports Eye Safety Awareness Month, Amanda Nanasy, OD, discussed her advice for maintaining proper eye health among athletes.

Maria Sampalis, OD, tells Diana Canto-Sims, OD, in this week's episode that the biggest impact AI has made at her practice is when used in the exam room as a scribe for routine patients.

Aldeyra Therapeutics will submit a FDRR to the FDA for reproxalap, an investigational drug or dry eye disease.